Recently, CanSino disclosed its 2023 annual performance forecast.
According to the data, the company is expected to lose 12$6.8 billion to $149.6 billion yuan, the amount of pre-loss ranks among the top Shenwan pharmaceutical and biological companies that have disclosed their 2023 performance forecasts.
As of the end of the third quarter of 2023, the company has 322.1 billion yuan, short-term borrowings and long-term borrowings amounted to 8300 million yuan, 94.5 billion yuan.
In 2023, the pre-loss will exceed 1.2 billion.
According to the announcement, CanSino expects that the net profit attributable to the owners of the parent company in 2023 will be a loss compared with the same period last year, and the net profit attributable to the owners of the parent company will be -126,853$870,000 to -149,687$560,000.
"The main reason for the increase in the company's net loss attributable to owners of the parent company compared with the same period last year is that the company's new crown vaccine-related revenue decreased significantly compared with the same period last year due to changes in the market demand for new crown vaccines," CanSino saidBased on the actual vaccination of new crown vaccine products and the expectation of future vaccination, the company calculated and reasonably estimated the amount of new crown vaccine product returns that have occurred and may occur in the future, and wrote off the revenue ...... new crown vaccine products during the reporting period”
CanSino was listed on the Hong Kong stock market in 2019 and listed on the A-share Science and Technology Innovation Board in 2020. Since its listing in 2019, CanSino has suffered losses in most years, but in 2021, it will achieve a net profit attributable to the parent company of 19RMB1.4 billion, mainly due to the conditional marketing approval and emergency use authorization of the recombinant novel coronavirus vaccine (adenovirus type 5 vector) in many countries at home and abroad, and the commercialization of the product had a positive impact on the company's total operating revenue and related profit indicators.
Monetary funds on the account 322.1 billion yuan, with a high point of more than 90% of the stock price**
As of the end of the third quarter of 2023, CanSino has 322.1 billion yuan, short-term borrowings and long-term borrowings amounted to 8300 million yuan, 94.5 billion yuan.
As of Feb. 20**, CanSino (688185SH) share price is 5427 yuan shares (before the resumption, the same below), compared with the 2021 high** more than 90%, the market value fell below 15 billion.
Since 2021, CanSino (688185SH) share price for 4 consecutive years**, including ** in 2022 and 202397%。
Article serial number: 1759821251049820160).
Disclaimer: This article does not constitute any investment advice to anyone.
Intellectual Property Statement: The intellectual property rights of Bread Finance works are owned by Shanghai Miaotan Network Technology.